Esophageal disease after stem cell transplantation

Esophageal involvement in graft-versus-host disease after transplant is uncommon, but it can be severe and emerge months or years after allogeneic haematopoietic stem cell transplantation. Donor immune cells may injure the recipient’s gastrointestinal tract, while long-term inflammation can produce fibrosis, strictures and substantial nutritional problems.

The 17th World Congress for Esophageal Diseases, held virtually from 27–30 September 2021, addressed these issues through scientific sessions, workshops and abstract presentations. For Australian clinicians and patients, timely access to endoscopy, subsidised treatment and coordinated follow-up remains central, particularly when chronic graft-versus-host disease continues after the initial transplant.

Why immune injury reaches the oesophagus

Allogeneic transplantation introduces donor immune cells that can recognise recipient tissues as foreign. In the oesophagus, acute graft-versus-host disease may cause basal-cell apoptosis and lichenoid inflammation; chronic disease can extend to submucosal fibrosis and fixed narrowing. The ISDE 2021 programme and access information are available through congress registration, giving clinicians a relevant setting for discussing immune-mediated disease.

Risk depends on donor type, conditioning, graft matching, infection and immunosuppression. Oesophageal disease is uncommon, so symptoms alone are insufficient for diagnosis. Clinicians must combine transplant timing, endoscopic findings, biopsy interpretation and exclusion of competing causes.

Symptoms that require careful interpretation

Odynophagia, dysphagia, retrosternal discomfort, heartburn, early satiety and weight loss may signal oesophageal involvement. Bleeding or sudden inability to swallow liquids are urgent features. Patients may take smaller bites, avoid restaurants or change their diet, adaptations that can conceal nutritional decline rather than solve it.

Care is stronger when oral and gastrointestinal clues are reviewed together, especially if lichenoid mouth lesions or dry mouth coexist. The Per-IADR 2020 meeting illustrates the value of linking oral and systemic inflammatory research. In Australia, widely available antacids may also blur the symptom pattern, so new reflux treatments should not prevent investigation of persistent dysphagia.

Building a diagnosis in Australian centres

Major allogeneic transplant services in Melbourne and Sydney bring together haematology, gastroenterology, pathology and dietetic expertise. Targeted oesophageal biopsy is central, with expert review when findings are subtle. Normal-looking mucosa does not completely exclude graft-versus-host disease, and infection, medication injury, peptic ulceration and radiation can alter management.

Patients outside cities may depend on telehealth and travel for endoscopy, making shared records and coordinated appointments important. Medicare generally covers public hospital treatment, while private insurance and out-of-pocket expenses affect some pathways. PBS subsidies and hospital formularies also influence access to systemic therapy.

Acute disease after transplantation

Acute oesophageal graft-versus-host disease usually occurs within 100 days of transplantation and may accompany skin, gut or liver involvement. Endoscopy may show erythema, erosions or sloughing, while biopsy demonstrates epithelial injury. Its timing and appearance can closely resemble viral or fungal oesophagitis.

Because these conditions can coexist, tissue diagnosis matters, particularly with odynophagia, fever or bleeding. The transplant team must balance anti-inflammatory treatment with infection assessment and overall immunosuppression. Deteriorating hydration or intake makes watchful waiting inappropriate.

Chronic inflammation and fixed narrowing

Chronic disease usually begins after 100 days and may develop without a recognisable acute phase. Oral lichenoid changes, dry mouth and skin or lung disease can accompany it. Persistent oesophageal inflammation may progress to fibrosis and strictures, causing progressive dysphagia, food retention and weight loss.

Strictures require repeated assessment because ongoing injury can create further scarring. Dilation may improve flow but does not remove the immune trigger. Texture modification and aspiration precautions are integral, and patients travelling from regional Australia to Melbourne or Sydney benefit from local dietetic support between specialist visits.

Treatment, access and coordinated care

No single drug suits every form of oesophageal graft-versus-host disease. Depending on severity and wider transplant status, teams may use systemic corticosteroids, other immunosuppressants, topical therapy or selected biologic agents, alongside infection prophylaxis and stricture management. Laboratory and clinical monitoring are essential because infection and drug toxicity are constant concerns.

Australian prescribing draws on PBS-listed medicines, hospital protocols and specialist pharmacy pathways. Patients should not change immunosuppressants or add unlabelled supplements without the transplant team, since interactions can destabilise graft control. Modified-texture foods and commercial supplements should be reviewed for swallowing safety and sugar content.

The transplant environment is also shaped by Australian law. Deceased organ and tissue donation operates under national arrangements, including the Organ and Tissue Donation After Death Act 2009 (Cth), together with state and territory requirements. Clinical teams should keep donation procedures and recipient care distinct and give families jurisdiction-specific information.

Long-term follow-up and patient priorities

Long-term care works best when the patient, haematologist, gastroenterologist, dietitian and general practitioner share one plan. Swallowing symptoms, weight, medicines, infections and endoscopic findings should be recorded in an accessible history. In a geographically dispersed country, shared protocols and telehealth reviews can reduce gaps, while local GPs support vaccination, medication reconciliation and early referral.

Persistent swallowing difficulty after transplantation should always be treated as a diagnostic and safety priority, not an incidental digestive complaint, because treatable immune injury, infection, stricture and nutritional compromise can coexist.